Clinical Trial: Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550231) titled 'Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee' on April 20.

Brief Summary: The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Osteoarthritis of the Knees

Intervention: DRUG: AD-211-L

Per oral, 1 tablet twice daily during the treatment period.

DRUG: AD-211-M

Per oral, 1 tablet twice daily during the treatment period.

DRUG: AD-211-H

Per oral, 1 tablet twice daily during the treatment period.

DRUG: AD-2113

Per oral, 1 tablet twice daily during the treatment ...